Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Abivax SA Sponsored ADR ( (ABVX) ).
Abivax SA, a clinical-stage biotechnology company focused on immune-regulating therapies for chronic inflammatory diseases, operates from France and the U.S. with a primary emphasis on its Phase 3 lead candidate obefazimod (ABX464) for moderately to severely active ulcerative colitis.
On May 11, 2026, Abivax held its annual ordinary and extraordinary general meeting, where shareholders approved all resolutions proposed by the board, including the 2025 financial statements, income allocation, compensation policies for the chair, CEO and directors, and delegations for financial transactions. The meeting showed strong shareholder engagement, with an 86.06% participation rate and broad support for governance and pay items, reinforcing the board’s mandate and financial flexibility.
The most recent analyst rating on (ABVX) stock is a Buy with a $148.00 price target. To see the full list of analyst forecasts on Abivax SA Sponsored ADR stock, see the ABVX Stock Forecast page.
Spark’s Take on ABVX Stock
According to Spark, TipRanks’ AI Analyst, ABVX is a Neutral.
The score is held down primarily by weak operating fundamentals (zero revenue in 2025, widening losses, and heavy cash burn). Technicals also lean bearish with the price below key moving averages and negative MACD. The main stabilizer is the improved balance sheet with low leverage and a larger equity base.
To see Spark’s full report on ABVX stock, click here.
More about Abivax SA Sponsored ADR
Abivax SA is a clinical-stage biotechnology company developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, its lead drug candidate, obefazimod (ABX464), is in Phase 3 trials for moderately to severely active ulcerative colitis.
Average Trading Volume: 950,701
Technical Sentiment Signal: Buy
Current Market Cap: $8.84B
Find detailed analytics on ABVX stock on TipRanks’ Stock Analysis page.